Lil­ly joins in ex­pand­ed Se­ries A round for BeiGene-part­nered mR­NA biotech

With the buzz around the Covid-19 mR­NA vac­cines wear­ing off, biotechs at­tempt­ing to cre­ate the next gen­er­a­tion of mes­sen­ger RNA ther­a­peu­tics are in full swing, and MIT-found­ed Strand Ther­a­peu­tics has picked up $45 mil­lion more to do so.

The Boston-based drug de­vel­op­er added that amount to its orig­i­nal $52 mil­lion Se­ries A, dis­closed in June 2021, to get its first sol­id tu­mor mR­NA can­di­date in­to hu­man tri­als next year. The BeiGene-part­nered start­up gath­ered the Se­ries A1 funds from Eli Lil­ly, FPV, Po­ten­tum Part­ners, ex­ist­ing backer Play­ground Glob­al and an “unan­nounced syn­di­cate.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER